- Home
- PNI vs MDXH Comparison
PNI vs MDXH Comparison
Compare PNI & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNI
- MDXH
- Stock Information
- Founded
- PNI 2002
- MDXH 2003
- Country
- PNI United States
- MDXH Belgium
- Employees
- PNI N/A
- MDXH N/A
- Industry
- PNI Trusts Except Educational Religious and Charitable
- MDXH
- Sector
- PNI Finance
- MDXH
- Exchange
- PNI Nasdaq
- MDXH Nasdaq
- Market Cap
- PNI 82.7M
- MDXH 73.3M
- IPO Year
- PNI N/A
- MDXH 2021
- Fundamental
- Price
- PNI $6.69
- MDXH $1.60
- Analyst Decision
- PNI
- MDXH Buy
- Analyst Count
- PNI 0
- MDXH 1
- Target Price
- PNI N/A
- MDXH $6.00
- AVG Volume (30 Days)
- PNI 26.4K
- MDXH 42.3K
- Earning Date
- PNI 01-01-0001
- MDXH 04-30-2025
- Dividend Yield
- PNI 4.76%
- MDXH N/A
- EPS Growth
- PNI N/A
- MDXH N/A
- EPS
- PNI N/A
- MDXH N/A
- Revenue
- PNI N/A
- MDXH $90,049,000.00
- Revenue This Year
- PNI N/A
- MDXH $23.38
- Revenue Next Year
- PNI N/A
- MDXH $16.84
- P/E Ratio
- PNI N/A
- MDXH N/A
- Revenue Growth
- PNI N/A
- MDXH 28.29
- 52 Week Low
- PNI $6.03
- MDXH $1.35
- 52 Week High
- PNI $7.89
- MDXH $3.50
- Technical
- Relative Strength Index (RSI)
- PNI 29.75
- MDXH 54.49
- Support Level
- PNI $6.64
- MDXH $1.51
- Resistance Level
- PNI $6.91
- MDXH $1.64
- Average True Range (ATR)
- PNI 0.15
- MDXH 0.08
- MACD
- PNI -0.03
- MDXH 0.02
- Stochastic Oscillator
- PNI 25.00
- MDXH 85.71
About PNI Pimco New York Municipal Income Fund II of Beneficial Interest
PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.